natgillin/translations-raw huggingface dataset:
Across the three Phase III placebo-controlled clinical studies (colorectal, pancreatic, and lung cancer populations), the incidence of compromised wound healing (all grades) was 0.5% for patients treated with ZALTRAP and 0.4% for patients treated with placebo.
V treh s placebom kontroliranih kliničnih študijah III. faze (populacije s kolorektalnim rakom, rakom pankreasa in pljučnim rakom) je bila incidenca slabšega celjenja ran (vseh stopenj) med prejemniki zdravila ZALTRAP 0,5 % in med prejemniki placeba 0,4 %.
Across the three Phase III placebo-controlled clinical studies (colorectal, pancreatic, and lung cancer populations), the incidence of fistula (all grades) was 1.1% for patients treated with ZALTRAP and 0.2% for patients treated with placebo.
V treh s placebom kontroliranih kliničnih študijah III. faze (populacije s kolorektalnim rakom, rakom pankreasa in pljučnim rakom) je bila incidenca fistul (vseh stopenj) med prejemniki zdravila ZALTRAP 1,1 % in med prejemniki placeba 0,2 %.
Across the three Phase III placebo-controlled clinical studies (colorectal, pancreatic, and lung cancer populations), the incidence of GI perforation (all grades) was 0.8% for patients treated with ZALTRAP and 0.3% for patients treated with placebo.
V treh s placebom kontroliranih kliničnih študijah III. faze (populacije s kolorektalnim rakom, rakom pankreasa in pljučnim rakom) je bila incidenca perforacij prebavil (vseh stopenj) 0,8 % med prejemniki zdravila ZALTRAP in 0,3 % med prejemniki placeba.
Across the three Phase III placebo-controlled clinical studies (colorectal, pancreatic, and lung cancer populations), the incidence of VTE (all grades) was 7.1% for patients treated with ZALTRAP and 7.1% for patients treated with placebo.
V vseh treh s placebom kontroliranih kliničnih študijah III. faze (populacije s kolorektalnim rakom, rakom pankreasa in pljučnim rakom) je bila incidenca VTE (vseh stopenj) 7,1 % med prejemniki zdravila ZALTRAP in 7,1 % med prejemniki placeba.
Across the two studies, among the patients who received 300 mg/m2, about half of them responded to treatment, according the doctor’s grading.
V dveh študijah z bolniki, ki so prejemali 300 mg/m2 zdravila, se jih je glede na zdravniško oceno na zdravljenje odzvala približno polovica.
acs of fluid within the ovaries (ovarian cysts)
vrečke s tekočino v jajčnikih (ovarijske ciste)
ACS patients with prior ischaemic stroke can be treated with Brilique for up to 12 months (PLATO study).
Bolniki z AKS in predhodno ishemično možgansko kapjo lahko prejemajo zdravljenje z zdravilom Brilique do 12 mesecev (študija PLATO).
ACT I and ACT III studied the effect of BRINAVESS in the treatment of patients with sustained atrial fibrillation > 3 hours but not more than 45 days in duration.
Študiji ACT I in ACT III sta preučevali učinek zdravila BRINAVESS pri bolnikih z obstojno atrijsko fibrilacijo, ki je trajala > 3 ure in ne več kot 45 dni.
ACT II examined the effect of BRINAVESS on patients who developed atrial fibrillation of < 3 days duration after recently undergoing coronary artery bypass graft, (CABG) and/or valvular surgery (atrial fibrillation occurred more than 1 day but less than 7 days after surgery).
Študija ACT II je preučevala učinek zdravila BRINAVESS pri bolnikih, ki se jim je pojavila < 3 dni trajajoča atrijska fibrilacija po nedavni obvodni koronarni operaciji (CABG) in/ali operaciji zaklopk (atrijska fibrilacija se je pojavila več kot 1 dan, a manj kot 7 dni po operaciji).
Act.: {Y} GBq/vial Cal : {DD/MM/YYYY} (12 h CET) Act.: {Y} GBq/ml Cal: {DD/MM/YYYY} (12 h CET)
Akt.: {Y} GBq/vialo Kal.: {DD/MM/LLLL} (12h po srednjeevropskem času) Akt.: {Y} GBq/ml Kal.: {DD/MM/LLLL} (12h po srednjeevropskem času)
Act.: {Y} GBq/vial Cal.: {DD/MM/AAAA} (12h CET)
Akt.: {Y} GBq/vial Kal.: {DD/MM/LLLL} (12h CET)
Act.: {Y} GBq/vial Cal.: {DD/MM/AAAA} (12h CET)
Akt.: {Y} GBq/vialo Kal.: {DD/MM/LLLL} (12h po srednjeevropskem času)
Actavis Group PTC ehf. (logo)
Actavis Group PTC ehf.
Actavis hf Reykjavíkurvegur 76 - 78 IS-220 Hafnarfjördur Iceland
Actavis hf Reykjavíkurvegur 76 - 78 IS-220 Hafnarfjördur Islandija
Actelion Pharmaceuticals UK Ltd Tel: +44 208 987 3333
Actelion Pharmaceuticals UK Ltd Tel: +44-208 987 3333
Actelsar HCT 40 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by telmisartan 40 mg
Zdravilo Actelsar HCT 40 mg/12,5 mg lahko dajemo enkrat na dan bolnikom, pri katerih krvnega tlaka ne moremo ustrezno nadzorovati s telmisartanom 40 mg.
Actelsar HCT 40 mg/12.5 mg tablets are white or almost white, 6.55 x 13.6 mm oval-shaped and biconvex tablets marked with “TH” on one side.
Tablete zdravila Actelsar HCT 40 mg/12,5 mg tablete so bele ali skoraj bele, velikosti 6,55 x 13,6 mm, ovalne in bikonveksne tablete, z oznako “TH” na eni strani.
Actelsar HCT 80 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by telmisartan 80 mg
Zdravilo Actelsar HCT 80 mg/12,5 mg lahko dajemo enkrat na dan bolnikom, pri katerih krvnega tlaka ne moremo ustrezno nadzorovati s telmisartanom 80 mg.
Actelsar HCT 80 mg/12.5 mg tablets are white or almost white, 9.0 x 17.0 mm capsule-shaped tablets marked with “TH 12.5” on both sides.
Tablete zdravila Actelsar HCT 80 mg/12,5 mg tablete so bele ali skoraj bele, 9.0 x 17.0 mm, v obliki kapsule, z oznako “TH 12,5” na obeh straneh.
Actelsar HCT 80 mg/12.5 mg tablets are white or almost white, 9.0 x 17.0 mm capsule-shaped tablets marked with “TH 12.5” on both sides.
Tablete zdravila Actelsar HCT 80 mg/12,5 mg tablete so bele ali skoraj bele, velikosti 9.0 x 17.0 mm, v obliki kapsule, z oznako “TH 12,5” na obeh straneh.
Actelsar HCT 80 mg/25 mg may be administered once daily in patients whose blood pressure is not adequately controlled by Actelsar HCT 80 mg/12.5 mg or in patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
Zdravilo Actelsar HCT 80 mg/25 mg lahko dajemo enkrat na dan bolnikom, pri katerih krvnega tlaka ne moremo ustrezno nadzorovati z zdravilom Actelsar HCT 80 mg/12,5 mg ali bolnikom, ki jemljejo telmisartan in hidroklorotiazid posebej in imajo ustaljen krvni tlak.
Actelsar HCT 80 mg/25 mg tablets are white or almost white, 9.0 x 17.0 mm oval-shaped and biconvex tablets marked with “TH” on one side and “25” on the other side.
Tablete zdravila Actelsar HCT 80 mg/25 mg tablete so bele ali skoraj bele, 9.0 x 17.0 mm, ovalne in bikonveksne tablete, z oznako “TH” na eni strani in “25” na drugi strani.
Actelsar HCT fixed dose combination (40 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.
Zdravilo Actelsar HCT, fiksna kombinacija (40 mg telmisartana in 12,5 mg hidroklorotiazida), je indicirano za odrasle, pri katerih krvnega tlaka ne moremo ustrezno uravnati s samim telmisartanom.
Actelsar HCT fixed dose combination (80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.
Zdravilo Actelsar HCT, fiksna kombinacija (80 mg telmisartana in 12,5 mg hidroklorotiazida), je indicirano za odrasle, pri katerih krvnega tlaka ne moremo ustrezno uravnati s samim telmisartanom.
Actelsar HCT fixed dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Actelsar HCT 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
Zdravilo Actelsar HCT, fiksna kombinacija (80 mg telmisartana in 25 mg hidroklorotiazida), je indicirano za odrasle, pri katerih krvnega tlaka ne moremo ustrezno uravnati z zdravilom Actelsar HCT 80 mg/12,5 mg (80 mg telmisartana in 12,5 mg hidroklorotiazida) ali za bolnike, ki jemljejo telmisartan in hidroklorotiazid posebej in imajo ustaljen krvni tlak.
Actelsar HCT is a ‘generic medicine’.
Zdravilo Actelsar HCT je „generično zdravilo“.
Actelsar HCT may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine).
Zdravilo Actelsar HCT lahko poveča znižanje krvnega tlaka, ki ga povzročijo druga zdravila za zdravljenje visokega krvnega tlaka ali zdravila, ki lahko povzročijo znižanje krvnega tlaka (npr. baklofen, amifostin).
Actelsar HCT once daily produces effective and smooth reductions in blood pressure across the therapeutic dose range.
Zdravilo Actelsar HCT v enem odmerku na dan učinkovito in enakomerno znižuje krvni tlak v celotnem razponu odmerjanja.
Actelsar HCT should be used in patients whose blood pressure is not adequately controlled by telmisartan alone.
Bolniki, pri katerih krvnega tlaka ne moremo ustrezno uravnati s samim telmisartanom, jemljejo zdravilo Actelsar HCT.
Acticam 5 mg/ml solution for injection for dogs and cats
Acticam 5 mg/ml, raztopina za injiciranje za pse in mačke
Acticam contains meloxicam, which belongs to a class of medicines called non-steroidal anti- inflammatory drugs (NSAIDs).
Zdravilo Acticam vsebuje meloksikam, ki spada v skupino zdravil, ki jim pravimo nesteroidna protivnetna zdravila (NSPVZ).
Acticam is efficacious in alleviating the inflammation and pain in both acute and chronic musculo- skeletal disorders and reducing the post operative pain following orthopaedic and soft tissue surgery in dogs and in reducing the post-operative pain after ovariohysterectomy and minor soft tissue surgery in cats.
Zdravilo Acticam je učinkovito pri umirjanju vnetja in lajšanju bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih ter lajšanju pooperativne bolečine po ortopedskih operacijah in operacijah mehkega tkiva pri psih ter lajšanju pooperativne bolečine po ovariohisterektomiji in manjših operacijah mehkega tkiva pri mačkah.
Actinic keratoses do not occur in children and adolescents.
Aktinične keratoze se pri otrocih in mladostnikih ne pojavljajo.
Actinic keratosis
aktinična keratoza
Actinic keratosis is a condition not generally seen within the paediatric population and was not studied.
Aktinična keratoza je stanje, ki ga navadno ne opazimo pri otrocih, in ga pri tej populaciji niso preučevali.
Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight.
Aktinične keratoze so predrakave, nenormalne kožne tvorbe, ki se razvijejo po čezmernem izpostavljanju sončni svetlobi.
Actinic keratosis lesion severity was graded according to the scale described by Olsen et al., 1991 (J Am Acad Dermatol 1991; 24: 738-743):
Resnost lezij aktinične keratoze se je ocenjevala v skladu z lestvico po Olsenu et al., 1991 (J Am Acad Dermatol, 1991; 24: 738–743):
Actinic keratosis lesions or fields should be evaluated three months after treatment.
Lezije aktinične keratoze ali polja je treba oceniti tri mesece po zdravljenju.
actinic keratosis lesions were cleared. c Median percent (%) reduction in actinic keratosis lesions compared to baseline. d p<0.001; compared to vehicle by logistic regression with treatment, study and anatomical location.
izhodiščnih lezij zaradi aktinične keratoze. c Mediano odstotno zmanjšanje (%) lezij zaradi aktinične keratoze v primerjavi z izhodiščem. d p < 0,001; v primerjavi z vehiklom glede na logistično regresijo z zdravljenjem, študijo in anatomsko umestitvijo.
Actinic Keratosis of the Face and Scalp, sequential use after cryotherapy
Aktinična keratoza obraza in lasišča, sekvenčno zdravljenje po krioterapiji
Actinic keratosis on the trunk and extremities in adults
Aktinična keratoza na trupu in okončinah pri odraslih bolnikih
Action on previous dose
Dejanje glede na prejšnji odmerek
ACTIONS TO TAKE IN CASE OF SIDE EFFECTS
UKREPI V PRIMERU POJAVA NEŽELENIH UČINKOV
Activate the pen on the same day as your first injection
Aktivirajte peresnik na dan, ko boste zdravilo prvič injicirali
Activate the pen on the same day as your first injection.
Aktivirajte peresnik na dan, ko boste zdravilo prvič injicirali.
Activate the safety guard over the needle, in one of the two methods shown:
Aktivirajte varnostni ščitnik, da pokrije iglo, in sicer na enega od dveh prikazanih načinov:
Activate the safety guard over the needle, in one of the two methods shown: either press the hinged section of the safety guard down onto a hard surface (figure A), or push the hinge forward with your finger (figure B).
Aktivirajte varnostni ščitnik, da pokrije iglo, in sicer na enega od dveh prikazanih načinov: bodisi pritisnite zglob varnostnega ščitnika navzdol ob trdo površino (slika A), ali pa zglob potisnite naprej s prstom (slika B).
Activated charcoal
Aktivno oglje
Activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60 % and should be taken at least 2 hours before or after olanzapine.
Aktivno oglje zmanjša biološko uporabnost peroralnega olanzapina za 50 do 60 % in ga je treba zaužiti vsaj 2 dve uri pred olanzapinom ali vsaj 2 uri po njem.
Activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60 % and should be taken at least 2 hours before or after olanzapine.
Aktivno oglje zmanjša biološko uporabnost peroralnega olanzapina za 50 do 60 % in ga je treba zaužiti vsaj uri pred olanzapinom ali vsaj 2 uri po njem.
Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X. Activated factor X converts prothrombin into thrombin.
Virkjaður storkuþáttur VIII verkar sem hjálparþáttur (cofactor) virkjaðs storkuþáttar IX og hraðar umbreytingu á storkuþætti X í virkjaðan storkuþátt X. Virkjaður storkuþáttur X umbreytir prótrombíni í trombín.
Activated partial thromboplastin time (aPTT) assay
Test za določanje aktiviranega delnega tromboplastinskega časa (aPTT)
activated partial thromboplastin time prolonged, neutralizing antibody positive
podaljšan aktivirani parcialni tromboplastinski čas, pozitivna nevtralizirajoča protitelesa
Activated renin-angiotensin-aldosterone system (RAAS)
Aktiviran sistem renin-angiotenzin-aldosteron (RAAS)
Activation button
Sprožilni gumb
Activation clips
mehanizma
Activation is done to make sure that the pen is working correctly and that the dose for your first injection is correct.
Aktivacija je potrebna, da preverite pravilno delovanje peresnika in zagotovite, da je odmerek za vaše prvo injiciranje pravilen.
Activation of human macrophages by mifamurtide is associated with production of cytokines, including tumour necrosis factor (TNF-), interleukin-1 (IL-1), IL-6, IL-8, and IL-12 and adhesion molecules, including lymphocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule- 1 (ICAM-1).
Aktivacija človeških makrofagov z mifamurtidom je povezana s produkcijo citokinov, vključno s faktorjem tumorske nekroze (TNF-), interlevkinom-1 (IL-1), IL-6, IL-8 in IL-12, ter adhezijskih molekul, ki zajemajo z delovanjem limfocita povezan antigen-1 (LFA-1) in intercelularno adhezijsko molekulo-1 (ICAM-1).
Activation of infection (tuberculosis, fungal and viral infections including herpes).
Sprožitev okužbe (tuberkuloza, glivične in virusne okužbe, vključno s herpesom).
Activation of mania and hypomania have been reported in patients with mood disorders who were treated with other similar medicinal products for major depressive disorder.
O aktivaciji manije in hipomanije so poročali pri bolnikih z razpoloženjskimi motnjami, ki so bili zdravljeni s podobnimi zdravili za veliko depresivno motnjo.
Activation of PPARα also induces an increase in the synthesis of Apoproteins A-I, A-II and of HDL cholesterol.
Aktivacija PPARα vzpodbudi tudi hitrejšo sintezo apoproteinov A-I in A-II ter holesterola HDL.
Activation window
O peresniku Lyxumia
Active
Norelgestro- min
active + 24 placebo)
placebo)
active + 52 placebo)
placebo)
Active and latent tuberculosis have been reported in 0.3% of the patients treated with LEMTRADA, most often in endemic regions.
Aktivno in latentno tuberkulozo so ugotovili pri 0,3 % bolnikov, zdravljenih z zdravilom LEMTRADA, najpogosteje v endemskih področjih.
Active and passive immunisation of pigs against Aujeszky’s disease.
Aktivna in pasivna imunizacija prašičev proti Aujeszkyjevi bolezni.
active bleeding or increased risk of bleeding because of haemostasis disorders and/or irreversible coagulation disorders
aktivno krvavitvijo ali povečanim tveganjem za krvavitve zaradi motenj hemostaze ali trajnih motenj koagulacije ali obojega.
active bleeding or increased risk of bleeding because of haemostasis disorders and/or irreversible coagulation disorders
aktivno krvavitvijo ali povečanim tveganjem za krvavitve zaradi motenj hemostaze ali trajnih motenj koagulacije ali obojega;
Active bleeding or increased risk of bleeding, because of impaired haemostasis and/or irreversible coagulation disorders or due to recent major surgery/trauma or uncontrolled severe hypertension.
Aktivna krvavitev ali večje tveganje za krvavitev zaradi okvare hemostaze in/ali ireverzibilne motnje koagulacije ali zaradi nedavne velike operacije/poškodbe ali neobvladane hude hipertenzije.
Active bleeding, especially intracranial or gastrointestinal haemorrhage;
aktivne krvavitve, še posebno intrakranialne ali gastrointestinalne krvavitve;
active clinically significant bleeding
Sveža klinično pomembna krvavitev
active clinically significant bleeding
Sveža klinično pomembna krvavitev.
Active clinically significant bleeding.
Aktivna, klinično pomembna krvavitev.
Active comparator
Primerjaln a zdravilna učinkovina
Active Comparator Trials (n=2569) Evaluable Patients
Ocenljivi bolniki v preskušanjih z aktivnim primerjalnim zdravilom (n = 2569)
Active components
Zdravilne učinkovine
Active Control (laser) (N = 132)
) (N = 132)
Active Control (laser) (N = 132)
aktivna kontrola (lasersko zdravljenje) (N = 132)
Active Control (laser) (N = 154)
) (N = 154)
Active Control (laser) (N = 154)
aktivna kontrola (lasersko zdravljenj e) (N = 154)
Active Control (laser) (N = 90)
aktivna kontrola (lasersko zdravljenje) (N = 90)
Active controlled studies
Študije nadzorovane z učinkovino
Active dose regimen
Režim odmerjanja zdravilne učinkovine
Active gastric and/or duodenal ulceration,
aktivna razjeda na želodcu in/ali dvanajstniku,
Active immunisation against avian infectious bronchitis virus variant strain IB 4-91 which causes infectious bronchitis in chickens.
Aktivna imunizacija piščancev proti kužnemu bronhitisu, ki ga povzroča variantni sev IB 4-91.
Active immunisation against avian influenza type A, subtype H5.
Aktivna imunizacija proti aviarni influenci tipa A, podtip H5
Active immunisation against avian influenza type A, subtype H7N1.
Aktivna imunizacija proti aviarni influenci tipa A, podtip H7N1.
Active immunisation against disease caused by Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (including sepsis, meningitis, pneumonia, bacteraemia and acute otitis media) in infants and children from 2 months up to 5 years of age (see sections 4.2, 4.4 and 5.1).
Aktivna imunizacija proti boleznim, ki jih povzroča Streptococcus pneumoniae serotipov 4, 6B, 9V, 14, 18C, 19F in 23F (vključno s sepso, meningitisom, pljučnico, bakteriemijo in akutnim vnetjem srednjega ušesa) pri dojenčkih in otrocih od 2. meseca do 5. leta starosti (glejte poglavja 4.2, 4.4 in 5.1).
Active immunisation against disease caused by Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (including sepsis, meningitis, pneumonia, bacteraemia and acute otitis media) in infants and children from 2 months up to 5 years of age (see sections 4.2, 4.4 and 5.1).
Aktivna imunizacija proti boleznim, ki jih povzroča Streptococcus pneumoniae serotipov 4, 6B, 9V, 14, 18C, 19F in 23F (vključno s sepso, meningitisom, pljučnico, bakteriemijo in akutnim vnetjem srednjega ušesa), pri dojenčkih in otrocih od 2. meseca do 5. leta starosti (glejte poglavja 4.2, 4.4 in 5.1).
Active immunisation against invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants and children from 6 weeks up to 5 years of age.
Aktivna imunizacija proti invazivnim boleznim, pljučnici in akutnim vnetjem srednjega ušesa, ki jih povzroča Streptococcus pneumoniae pri dojenčkih in otrocih od 6. tedna do 5. leta starosti.
Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in adults ≥ 18 years of age and the elderly.
Aktivna imunizacija za preprečevanje invazivnih bolezni in pljučnice, ki jih povzroča Streptococcus pneumoniae, pri odraslih, starih 18 let in več, ter starejših.
Active immunisation of bitches to prevent mortality, clinical signs and lesions in puppies resulting from canine herpes virus infections acquired in the first few days of life through passive immunity.
Aktivna imunizacija psic in posledično preprečevanje smrtnosti, kliničnih znakov in poškodb pri mladičih (s pasivno imunostjo), ki so posledica okužbe mladičev s pasjim herpesvirusom v prvih dneh življenja.
Active immunisation of cats aged 8 weeks and older:
Aktivna imunizacija 8 tednov starih mačk in starejših:
Active immunisation of cattle from 3 months of age for the prevention of viraemia caused by bluetongue virus, serotypes 1 and 8.
Aktivna imunizacija goveda, starejšega od 3 mesecev, za preprečitev viremije, ki jo povzroča virus modrega jezika, serotipa 1 in 8.
Active immunisation of cattle from 3 months of age for the prevention* of viraemia caused by bluetongue virus (BTV), serotypes 1 and 8.
Aktivna imunizacija goveda, starejšega od 3 mesecev, za preprečitev* viremije, ki jo povzroča virus modrega jezika, serotipa 1 in 8.
Active immunisation of cattle from 3 months of age for the prevention* of viraemia caused by bluetongue virus, serotypes 1 and 8.
Aktivna imunizacija goveda, starejšega od 3 mesecev, za preprečitev* viremije, ki jo povzroča virus modrega jezika, serotipa 1 in 8.
Active immunisation of cattle to reduce the clinical signs of infectious bovine rhinotracheitis (IBR) and field virus excretion.
Aktivna imunizacija goveda za ublažitev kliničnih znakov kužnega govejega rinotraheitisa (IBR) in izločanja virusa v naravo.
Active immunisation of cattle, sheep and pigs from 2 weeks of age against foot-and-mouth disease to reduce clinical signs.
Aktivna imunizacija goveda, ovc in prašičev od 2 tednov starosti proti slinavki in parkljevki za zmanjšanje pojavnosti kliničnih znakov.
Active immunisation of cattle, sheep and pigs from 2 weeks of age against foot-and-mouth disease to reduce clinical signs.
Aktivna imunizacija goveda,ovc in prašičev od 2 tednov starosti proti bolezni slinavke in parkljavke za zmanjšanje kliničnih znakov.
Active immunisation of dogs from 6 weeks of age. to prevent clinical signs, infection and urinary excretion caused by L. interrogans serogroup Australis serovar Bratislava, to prevent clinical signs and urinary excretion and reduce infection caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterohaemorrhagie serovar Icterohaemorrhagiae and to prevent clinical signs and reduce infection and urinary excretion caused by L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa.
Aktivna imunizacija psov, starejših od 6 tednov: za preprečevanje kliničnih znakov, okužbe in izločanja z urinom, ki jih povzroča L. interrogans serološka skupina Australis, serovar Bratislava, za preprečevanje kliničnih znakov, izločanja z urinom in zmanjšanje okužb, ki jih povzroča L. interrogans, serološka skupina Canicola,serovar Canicola ter L. interrogans, serološka skupina Icterohaemorrhagiae, serovar Icterohaemorrhagiae in za preprečevanje kliničnih znakov, zmanjšanje okužbe in izločanja z urinom, ki jih povzroča L. kirschneri, serološka skupina Grippotyphosa, serovar Grippotyphosa.
Active immunisation of dogs from 6 weeks of age: to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus.
Aktivna imunizacija psov, starejših od 6 tednov: za preprečevanje kliničnih znakov (izcedek iz smrčka in oči) in zmanjšanje širjenja virusa, ki jih povzroča virus pasje parainfluence.
Active immunisation of dogs from 8-9 weeks of age:
Aktivna imunizacija psov, starejših od 8–9 tednov:
Active immunisation of dogs from 8–9 weeks of age:
Aktivna imunizacija psov, starejših od 8-9 tednov: